MGNX MacroGenics Inc.

25.37
+0.21  (+1%)
Previous Close 25.16
Open 25.17
Price To Book 6.54
Market Cap 1,246,631,491
Shares 49,138,017
Volume 754,351
Short Ratio
Av. Daily Volume 3,598,342
Stock charts supplied by TradingView

NewsSee all news

  1. MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO

    Rockville, MD, May 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  2. MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting

    Rockville, MD, May 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  3. MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results

    ROCKVILLE, Md., May 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  4. MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting

    Rockville, MD, April 29, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  5. MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format

    Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 enrolment has stopped - May 5, 2020.
Flotetuzumab
AML/MDS
BLA filing announced December 19, 2019. PDUFA date estimate December 18, 2020. FDA will require an Oncologic Drugs Advisory Committee (ODAC) meeting in the second half of 2020.
Margetuximab
Metastatic breast cancer
Phase 2 data due 2H 2020.
Retifanlimab INCMGA0012
Anal cancer
Phase 2/3 trial planned.
Enoblituzumab and MGA012
Solid tumors
Phase 1 partial clinical hold lifted January 25, 2019.
MGD009
Solid tumors
Phase 1 data to be presented at ASCO May 29, 2020.
MGD013 (ASCO)
Solid tumors
Phase 1 data to be presented 2H 2020.
MGD019
Solid tumors
Phase 2/3 initial data due 2H 2020.
Margetuximab and MGA012 (MAHOGANY)
Gastric cancer
Phase 2 trial initiation has been delayed due to COVID-19.
Enoblituzumab
Head and neck cancer

Latest News

  1. MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO

    Rockville, MD, May 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  2. MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting

    Rockville, MD, May 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  3. MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results

    ROCKVILLE, Md., May 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  4. MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting

    Rockville, MD, April 29, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  5. MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format

    Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  6. MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call

    Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  7. MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting

    Rockville, MD, April 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based

  8. MacroGenics Announces Departure of Chief Medical Officer

    Rockville, MD, March 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  9. MacroGenics to Participate in Upcoming Investor Conferences

    ROCKVILLE, MD, Feb. 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  10. MacroGenics Provides Update on Corporate Progress and 2019 Financial Results

    Margetuximab: BLA for metastatic HER2-positive breast cancer accepted for review by the FDA; Phase 2/3 MAHOGANY study ongoing in front-line advanced HER2-positive gastric cancerFirst clinical data from Phase 1/2 studies

  11. MacroGenics Announces Date of Fourth Quarter and Full Year 2019 Financial Results Conference Call

    Rockville, MD, Feb. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  12. MacroGenics to Participate in Upcoming Investor Conferences

    ROCKVILLE, MD, Feb. 10, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  13. MacroGenics to Present at the J.P. Morgan Healthcare Conference

    Rockville, MD, Jan. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  14. MacroGenics Outlines Corporate Priorities for 2020

    Rockville, MD, Jan. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  15. MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA

    ROCKVILLE, MD, Dec. 19, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  16. MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

    Rockville, MD, Dec. 11, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  17. MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting

    Rockville, MD, Dec. 09, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  18. MacroGenics to Participate in the Evercore ISI HealthCONx Conference

    Rockville, MD, Dec. 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  19. MacroGenics to Participate in Upcoming Investor Conferences

    Rockville, MD, Nov. 07, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  20. MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results

    ROCKVILLE, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  21. MacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019

    ROCKVILLE, MD, Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  22. MacroGenics Announces Date of Third Quarter 2019 Financial Results Conference Call

    Rockville, MD, Oct. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  23. MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

    ROCKVILLE, MD, Oct. 22, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  24. MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress

    ROCKVILLE, MD, Sept. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  25. MacroGenics to Participate in Cantor Global Healthcare Conference

    ROCKVILLE, MD, Sept. 26, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  26. MacroGenics to Participate in Upcoming Investor Conferences

    ROCKVILLE, MD, Aug. 29, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  27. INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati